Toril Holien

@torilhol.bsky.social

Prof. Cell & molecular biology. Educating biomedical scientists. Myeloma. TGFbeta. Cell signaling. Cancer. @NTNU & St. Olavs Hospital, Norway 🇳🇴. She/Her 🧪🧬🩸🔬 Orcid: https://orcid.org/my-orcid?orcid=0000-0002-2051-5824

Talquetamab–daratumumab, with or without pomalidomide, led to longer progression-free survival than daratumumab-based standard care in relapsed or refractory myeloma. More than 75% of patients had grade 3 or higher adverse events. Full MonumenTAL-3 trial results: https://nej.md/4ojBcCL #EHA2026

This image contains two Kaplan-Meier graphs comparing progression-free survival between different treatments over 36 months. Graph A shows "Tal-DP" and "DPd" treatment groups. Graph B shows "Tal-D" and "DPd" treatment groups. Both graphs display confidence intervals. The number of patients at risk is listed below each graph at different time points.

Still time to register & submit your abstract for a potential short talk! The FASEB TGF-β family in Development and Disease conference in Porto, July 26.-30. coming up. Early registration and extended abstract submission deadline is June 14th 👇 @mythreye.bsky.social events.faseb.org/event/TGF-B/...

Home - TGF-β Family in Development and Disease

Join leaders in TGF-β signaling to explore breakthroughs in development, disease, and therapy at this premier forum for basic and translational research.

events.faseb.org

Earlier this week I posted an example of a fake western blot provided by ThermoFisher to demonstrate the validity of a p53 antibody. I considered it an amusing curiosity. In fact Thermo Fisher Scientific has systematically manipulated antibody validation data!

Bild

Excited to announce the opening of the applications for the Master in Biomedical Research. An international, hands-on programme for students to think like scientists, work in real labs, and prepare for PhD training or R&D careers, in Lisbon. GIMM Institute 1/3

Bild
M